{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T11:44:53Z","timestamp":1774352693097,"version":"3.50.1"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JASN"],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:p>\n                           <jats:bold>Background<\/jats:bold> Although pharmacotherapeutic proteinuria lowering was found to be nephroprotective in adults, the predictive value of early drug-induced proteinuria reduction for long-term renal survival in pediatric CKD is unknown. We analyzed data from the ESCAPE Trial for a potential association between initial antiproteinuric effect of standardized angiotensin-converting enzyme (ACE) inhibition and renal disease progression in children with CKD.<\/jats:p>\n          <jats:p>\n                           <jats:bold>Methods<\/jats:bold> In total, 280 eligible children with CKD stages 2\u20134 (mean age 11.7 years old, median eGFR 46 ml\/min per 1.73 m<jats:sup>2<\/jats:sup>, 71% congenital renal malformations) received a fixed dose of ramipril (6 mg\/m<jats:sup>2<\/jats:sup> per day) and were subsequently randomized to conventional or intensified BP control. We assessed initial proteinuria reduction from baseline to first measurement on ramipril (at 2.5\u00b11.3 months). We used multivariable Cox modeling to estimate the association between initial proteinuria reduction and the risk of reaching a renal end point (50% eGFR decline or ESRD), which occurred in 80 patients during 5 years of observation.<\/jats:p>\n          <jats:p>\n                           <jats:bold>Results<\/jats:bold> Ramipril therapy lowered proteinuria by a mean of 43.5% (95% confidence interval, 36.3% to 49.9%). Relative to proteinuria reduction &lt;30%, 30%\u201360% and &gt;60% reduction resulted in hazard ratios (95% confidence intervals) of 0.70 (0.40 to 1.22) and 0.42 (0.22 to 0.79), respectively. This association was independent of age, sex, CKD diagnosis, baseline eGFR, baseline proteinuria, initial BP, and concomitant BP reduction.<\/jats:p>\n          <jats:p>\n                           <jats:bold>Conclusions<\/jats:bold> The early antiproteinuric effect of ACE inhibition is associated with long-term preservation of renal function in children with CKD. Proteinuria lowering should be considered an important target in the management of pediatric CKD.<\/jats:p>","DOI":"10.1681\/asn.2018010036","type":"journal-article","created":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T15:15:17Z","timestamp":1529594117000},"page":"2225-2233","source":"Crossref","is-referenced-by-count":85,"title":["Early Proteinuria Lowering by Angiotensin-Converting Enzyme Inhibition Predicts Renal Survival in Children with CKD"],"prefix":"10.1681","volume":"29","author":[{"given":"Sophie M.","family":"van den Belt","sequence":"first","affiliation":[{"name":"Departments of Clinical Pharmacy and Pharmacology and"}]},{"given":"Hiddo J.L.","family":"Heerspink","sequence":"additional","affiliation":[{"name":"Departments of Clinical Pharmacy and Pharmacology and"}]},{"given":"Valentina","family":"Gracchi","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; and"}]},{"given":"Dick","family":"de Zeeuw","sequence":"additional","affiliation":[{"name":"Departments of Clinical Pharmacy and Pharmacology and"}]},{"given":"Elke","family":"W\u00fchl","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, University Clinic Heidelberg, Heidelberg, Germany"}]},{"given":"Franz","family":"Schaefer","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, University Clinic Heidelberg, Heidelberg, Germany"}]},{"name":"on behalf of the ESCAPE Trial Group","sequence":"additional","affiliation":[]}],"member":"276","published-online":{"date-parts":[[2018,6,21]]},"reference":[{"key":"B1-20231016","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1161\/01.CIR.0000031732.78052.81","article-title":"Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population.","volume":"106","author":"Hillege","year":"2002","journal-title":"Circulation"},{"key":"B2-20231016","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S2213-8587(15)00040-6","article-title":"Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: A collaborative meta-analysis of individual participant data.","volume":"3","author":"Matsushita","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B3-20231016","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1681\/ASN.2008060655","article-title":"Screening for albuminuria identifies individuals at increased renal risk.","volume":"20","author":"van der Velde","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"B4-20231016","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1093\/ndt\/gfv407","article-title":"Prevalence and distribution of (micro)albuminuria in toddlers.","volume":"31","author":"Gracchi","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"B5-20231016","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1161\/CIRCULATIONAHA.106.179568","article-title":"Cardiovascular risk reduction in high-risk pediatric patients: A scientific statement from the American Heart Association expert panel on population and prevention science; the councils on cardiovascular disease in the young, epidemiology and prevention, nutrition, physical activity and metabolism, high blood pressure research, cardiovascular nursing, and the kidney in heart disease; and the interdisciplinary working group on quality of care and outcomes research: Endorsed by the American Academy of Pediatrics.","volume":"114","author":"Kavey","year":"2006","journal-title":"Circulation"},{"key":"B6-20231016","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0140-6736(96)09260-4","article-title":"Randomised multicentre study of a low-protein diet on the progression of chronic renal failure in children.","volume":"349","author":"Wingen","year":"1997","journal-title":"Lancet"},{"key":"B7-20231016","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1053\/j.ajkd.2015.01.008","article-title":"Predictors of rapid progression of glomerular and nonglomerular kidney disease in children and adolescents: The chronic kidney disease in children (CKiD) cohort.","volume":"65","author":"Warady","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"B8-20231016","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1161\/01.CIR.0000139860.33974.28","article-title":"Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.","volume":"110","author":"de Zeeuw","year":"2004","journal-title":"Circulation"},{"key":"B9-20231016","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1001\/archinte.165.8.947","article-title":"The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: Results of the African American study of kidney disease and hypertension.","volume":"165","author":"Lea","year":"2005","journal-title":"Arch Intern Med"},{"key":"B10-20231016","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1681\/ASN.2006050445","article-title":"Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: Post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.","volume":"18","author":"Eijkelkamp","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"B11-20231016","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJMoa0902066","article-title":"Strict blood-pressure control and progression of renal failure in children.","volume":"361","author":"W\u00fchl","year":"2009","journal-title":"N Engl J Med"},{"key":"B12-20231016","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00467-016-3495-1","article-title":"Achieving remission of proteinuria in childhood CKD.","volume":"32","author":"Ruggenenti","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"B13-20231016","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0031-3955(16)36251-4","article-title":"The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents.","volume":"34","author":"Schwartz","year":"1987","journal-title":"Pediatr Clin North Am"},{"key":"B14-20231016","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s004670100567","article-title":"Impact of ACE I\/D gene polymorphism on congenital renal malformations.","volume":"16","author":"Hohenfellner","year":"2001","journal-title":"Pediatr Nephrol"},{"key":"B15-20231016","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1093\/ndt\/gfv429","article-title":"Individual long-term albuminuria exposure during angiotensin receptor blocker therapy is the optimal predictor for renal outcome.","volume":"31","author":"Felix Kr\u00f6pelin","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"B16-20231016","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1046\/j.1523-1755.2003.00033.x","article-title":"Retarding progression of chronic renal disease: The neglected issue of residual proteinuria.","volume":"63","author":"Ruggenenti","year":"2003","journal-title":"Kidney Int"},{"key":"B17-20231016","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.2337\/dc11-0324","article-title":"Initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: A post hoc analysis of the IRMA-2 trial.","volume":"34","author":"Hellemons","year":"2011","journal-title":"Diabetes Care"},{"key":"B18-20231016","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","article-title":"Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL.","volume":"65","author":"de Zeeuw","year":"2004","journal-title":"Kidney Int"},{"key":"B19-20231016","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/bcp.12655","article-title":"The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers.","volume":"80","author":"Schievink","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"B20-20231016","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1681\/ASN.2007050582","article-title":"ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy.","volume":"19","author":"Parving","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"B21-20231016","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1046\/j.1523-1755.2000.00818.x","article-title":"ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies1.","volume":"57","author":"Perna","year":"2000","journal-title":"Kidney Int"},{"key":"B22-20231016","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ki.2012.74","article-title":"Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers.","volume":"82","author":"Lambers Heerspink","year":"2012","journal-title":"Kidney Int"},{"key":"B23-20231016","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1681\/ASN.2011040430","article-title":"Sodium intake, ACE inhibition, and progression to ESRD.","volume":"23","author":"Vegter","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"B24-20231016","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/ndt\/17.1.64","article-title":"Prognostic indicators of IgA nephropathy in the Chinese--clinical and pathological perspectives.","volume":"17","author":"Li","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"B25-20231016","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1681\/ASN.2007050526","article-title":"Remission of proteinuria improves prognosis in IgA nephropathy.","volume":"18","author":"Reich","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"B26-20231016","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1053\/j.ajkd.2011.09.006","article-title":"Multiple versus single and other estimates of baseline proteinuria status as predictors of adverse outcomes in the general population.","volume":"59","author":"Bello","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"B27-20231016","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/ki.1989.190","article-title":"Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril.","volume":"36","author":"Heeg","year":"1989","journal-title":"Kidney Int"},{"key":"B28-20231016","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1592\/phco.29.9.1061","article-title":"Antiproteinuric and blood pressure-lowering effects of a fixed-dose combination of losartan and hydrochlorothiazide in hypertensive patients with stage 3 chronic kidney disease.","volume":"29","author":"Abe","year":"2009","journal-title":"Pharmacotherapy"},{"key":"B29-20231016","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1681\/ASN.2008060649","article-title":"High protein intake associates with cardiovascular events but not with loss of renal function.","volume":"20","author":"Halbesma","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"B30-20231016","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1681\/ASN.2007060693","article-title":"Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan.","volume":"19","author":"Vogt","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"B31-20231016","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.nut.2015.05.004","article-title":"Effect of urine urea nitrogen and protein intake adjusted by using the estimated urine creatinine excretion rate on the antiproteinuric effect of angiotensin II type I receptor blockers.","volume":"31","author":"Chin","year":"2015","journal-title":"Nutrition"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00001751-201808000-00023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T02:23:52Z","timestamp":1697423032000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001751-201808000-00023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,21]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2018010036","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,21]]}}}